NCT03347318 2026-03-19
PROFILING
Fondazione del Piemonte per l'Oncologia
Active not recruiting
Clinical Trials
43 trialsNCT04083976 2026-03-19
RAGNAR
Janssen Research & Development, LLC
Phase 2 Active not recruiting
NCT04491942 2026-03-19
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT06009926 2026-03-19
Evaluation of Broccoli Seed and Sprout Extract for Detoxification of Carcinogens in Firefighters
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06360588 2026-03-19
Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Loss (MATCH - Subprotocol Z1G)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT01064648 2026-03-18
Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT01434316 2026-03-18
Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT02453620 2026-03-18
Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT02535312 2026-03-18
Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT06136897 2026-03-18
Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06351371 2026-03-18
Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Mutations or Fusions (MATCH - Subprotocol K2)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06487858 2026-03-18
A Study of BGB-R046 as Monotherapy and in Combination With Tislelizumab in Solid Tumors
BeOne Medicines
Phase 1 Active not recruiting
NCT03600883 2026-03-16
A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)
Amgen
Phase 1/2 Active not recruiting
NCT05571839 2026-03-13
A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors
Seagen Inc.
Phase 1 Active not recruiting
NCT04897022 2026-03-12
A Study of Pembrolizumab and Radiation Therapy in People With Mesothelioma
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT06057922 2026-03-12
A Study YL201 in Patients With Selected Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2 Active not recruiting
NCT03074513 2026-03-11
Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04870788 2026-03-11
Mindfulness-Based Intervention for Latino Cancer Patients and Their Caregivers
M.D. Anderson Cancer Center
Phase NA Active not recruiting
NCT06367751 2026-03-11
LIQPLAT
University Hospital, Basel, Switzerland
Phase NA Active not recruiting
NCT05781048 2026-03-10
A Phase I Clinical Study of the Safety， Tolerability，Pharmacokinetics, and Initial Efficacy of HRS-6209 Monotherapy in Patients With Advanced Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Active not recruiting
NCT07450560 2026-03-10
Research on Real-time Proton Therapy Guidance Through Monitoring Proton Range Using All-digital PET
Anhui Provincial Cancer Hospital
Active not recruiting
NCT07461181 2026-03-10
A Study to Evaluate the Safety, Tolerability, PK, PD, and Preliminary Efficacy of CS01 in Patients With Locally Advanced or Metastatic Solid Tumors
Ruijin Hospital
Phase 1/2 Active not recruiting
NCT02285816 2026-03-09
MG1 Maraba/MAGE-A3, With and Without Adenovirus Vaccine With Transgenic MAGE-A3 Insertion in Incurable MAGE-A3-Expressing Solid Tumours
Canadian Cancer Trials Group
Phase 1/2 Active not recruiting
NCT05514132 2026-03-09
A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid Tumours
AstraZeneca
Phase 1 Active not recruiting
NCT02959463 2026-03-06
Pembrolizumab After Radiation Therapy in Treating Patients With Pleural Malignant Mesothelioma
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT04262466 2026-03-06
Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors
Immunocore Ltd
Phase 1/2 Active not recruiting
NCT01843374 2026-03-05
Tremelimumab
MedImmune LLC
Phase 2 Active not recruiting
NCT02701712 2026-03-05
MRgRT
University Health Network, Toronto
Phase NA Active not recruiting
NCT04028570 2026-03-05
SMARTER
University Health Network, Toronto
Phase NA Active not recruiting
NCT05951608 2026-03-05
A Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors
Akeso
Phase 1/2 Active not recruiting
NCT03313778 2026-03-04
KEYNOTE-603
ModernaTX, Inc.
Phase 1 Active not recruiting
NCT03207672 2026-03-03
Study of E7389 Liposomal Formulation in Participants With Solid Tumor
Eisai Inc.
Phase 1 Active not recruiting
NCT06057038 2026-03-03
A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors
Genmab
Phase 1 Active not recruiting
NCT06685068 2026-03-03
A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors
Genmab
Phase 1/2 Active not recruiting
NCT06715124 2026-03-02
QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations
Quanta Therapeutics
Phase 1 Active not recruiting
NCT03448042 2026-02-27
A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers
Genentech, Inc.
Phase 1 Active not recruiting
NCT04735978 2026-02-27
Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours
Replimune Inc.
Phase 1 Active not recruiting
NCT05109975 2026-02-27
A Study to Evaluate Safety and Preliminary Anti-tumor Activity of Debio 0123 as Monotherapy in Adult Participants With Advanced Solid Tumors
Debiopharm International SA
Phase 1 Active not recruiting
NCT05914376 2026-02-27
Safety of Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Tumors
Hangzhou Converd Co., Ltd.
Phase 1 Active not recruiting
NCT07137195 2026-02-27
Clinical Trial of the Safety and Efficacy of IBA Proton Therapy System PROTEUS® PLUS (Hebei)
Ion Beam Applications
Phase NA Active not recruiting
NCT04250155 2026-02-24
An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
Phase 1 Active not recruiting
NCT06422520 2026-02-23
A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors
BeOne Medicines
Phase 1 Active not recruiting
NCT04649385 2026-02-20
BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors
BeOne Medicines
Phase 1 Active not recruiting